Jan 22, 2025 · Inclisiran is FDA-approved to reduce low-density lipoprotein (LDL-C) levels, as an adjunct to diet and statin therapy in adults with primary hyperlipidemia including heterozygous familial hypercholesterolemia (HeFH).

Inclisiran, sold under the brand name Leqvio, is a medication used for the treatment of high low-density lipoprotein (LDL) cholesterol and for the treatment of people with atherosclerotic cardiovascular disease (ASCVD), ASCVD risk-equivalents, and heterozygous familial hypercholesterolemia (HeFH).

Inclisiran injection is used together with a proper diet, alone or together with other medicines (eg, statins), to treat heterozygous familial hypercholesterolemia (HeFH) in patients who need additional lowering of their LDL cholesterol.

LEQVIO is a small interfering RNA (siRNA) directed to PCSK9 (proprotein convertase subtilisin kexin type 9) mRNA indicated as an adjunct to diet and maximally tolerated statin therapy for the...

Nov 24, 2023 · Learn about the side effects of inclisiran, from common to rare, for consumers and healthcare professionals.

Basel, December 22, 2021 — Novartis today announced the US Food and Drug Administration (FDA) approval of Leqvio ® (inclisiran), the first and only small interfering RNA (siRNA) therapy to lower low-density lipoprotein cholesterol (also known as bad cholesterol or LDL-C) with two doses a year, after an initial dose and one at three months.

Jan 5, 2023 · Inclisiran is a first-in-class small interfering ribonucleic acid (siRNA) therapy which prevents hepatic PCSK9 production and can be administered every 6 months (after initial and 3-month doses) providing a convenient approach to lower LDL cholesterol.

Lowering low-density lipoprotein cholesterol (LDL-C) levels is a key strategy to prevent and treat AHD. Inclisiran is a novel siRNA drug that targets proprotein convertase subtilisin/kexin type 9 (PCSK9) gene expression and reduces LDL-C levels with only two or three injections per year.

Inclisiran is a cholesterol-lowering treatment that reduces levels of a ‘bad’ cholesterol, called low-density lipoprotein (LDL) cholesterol, in the blood. High LDL cholesterol is a well-known risk factor for heart and circulatory disease.

Indicated as an adjunct to diet and statin therapy for adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), to reduce low-density...